Начало・Списък с акции・Neurocrine Biosciences Inc

Neurocrine Biosciences Inc

Затворен

СекторЗдравеопазване

162.78 2.19

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

158.27

Максимум

162.27

Ключови измерители
By Trading Economics
Приходи	-54M 144M
Продажби	145M 959M
P/E Средно за сектора	24.303 68.51
EPS	2.36
Марж на печалбата	15.057
Служители	2,500
EBITDA	-64M 190M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+30.67% upside

Дивиденти
By Acuity
Следващи печалби	27.10.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-1B 17B
Предишно отваряне	160.59
Предишно затваряне	162.78

Настроения в новините

By Acuity

50%

168 / 340 Класиране в Healthcare

Neurocrine Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.08.2026 г., 19:36 ч. UTC

Neurocrine Biosciences Inc shares are lower during Thursday's session, continuing a decline since Wednesday's close, with no specific news identified.

5.08.2026 г., 23:46 ч. UTC

Neurocrine Biosciences Inc shares are higher in after-market trading, buoyed by investor interest despite disappointing private sector employment data.

4.08.2026 г., 19:26 ч. UTC

News

Wedbush raised its price target on Neurocrine Biosciences to $194, while Canaccord Genuity increased its target to $210. Shares are trading roughly flat.

3.08.2026 г., 20:51 ч. UTC

Neurocrine Biosciences Inc shares are higher in after-market trading, reflecting a positive trend in the biotechnology sector amid broader market gains.

31.07.2026 г., 23:56 ч. UTC

News

Citigroup maintained its Buy rating on Neurocrine Biosciences and raised its price target to $249. Shares are higher in after-market trading.

30.07.2026 г., 21:51 ч. UTC

News

Neurocrine Biosciences reported second-quarter revenues of $959 million and raised 2026 INGREZZA sales guidance, with shares trading higher in after-market hours.

29.07.2026 г., 18:46 ч. UTC

Neurocrine Biosciences Inc shares are trading lower today with no specific news identified. The stock fluctuated earlier in the session amid broader market activity.

28.07.2026 г., 23:41 ч. UTC

Neurocrine Biosciences Inc shares are higher in after-market hours, rebounding from an earlier dip and maintaining a position above the 20-day moving average.

27.07.2026 г., 19:21 ч. UTC

Social Media

Neurocrine Biosciences shares are higher as Cantor Schimmer ranks it among top picks, citing undervaluation and expected advancements in its portfolio.

24.07.2026 г., 20:07 ч. UTC

Neurocrine Biosciences Inc shares are higher today, despite an earlier pullback. Broader market sentiment is influenced by falling oil prices easing inflation concerns.

22.07.2026 г., 19:51 ч. UTC

News

Neurocrine Biosciences Inc. appointed Samir Siddhanti as Chief Business Officer. Despite this leadership change, shares are trading lower amid cautious investor sentiment.

21.07.2026 г., 19:51 ч. UTC

News

Neurocrine shares rise after Guggenheim raises price target to $200.

20.07.2026 г., 23:46 ч. UTC

Neurocrine Biosciences Inc is trading higher in after-market hours, maintaining a strong performance above its 20-day moving average and near its one-month range.

Сравнение с други в отрасъла

Ценова промяна

Neurocrine Biosciences Inc Прогноза

Ценова цел

By TipRanks

30.67% нагоре

12-месечна прогноза

Среден 211.04 USD 30.67%

Висок 249 USD

Нисък 170 USD

Според 26 анализатори от Wall Street, предложили 12-месечна ценова цел за Neurocrine Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

26 ratings

Купи

Задържане

Продай

Според 26 анализатори, дали борсови рейтинги на Neurocrine Biosciences Inc през последните 3 месеца.

Настроение

By Acuity

168 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.